Saturday, October 1, 2022
HomeChemistryUntargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder most...

Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder most cancers


  • Sung, H. et al. World Most cancers Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 International locations. CA. Most cancers J. Clin. 71, 209–249 (2021).

    Article 
    PubMed 

    Google Scholar
     

  • Robins, D. J. et al. Mp86-17 the 2017 American joint committee on most cancers eighth version most cancers staging handbook: modifications in staging tips for cancers of the kidney, renal pelvis and ureter, bladder, and urethra. J. Urol. 197, e1163 (2017).

    Article 

    Google Scholar
     

  • Troisi, J. et al. A serum metabolomic signature for the detection and grading of bladder most cancers. Appl. Sci. 11, 2835 (2021).

    CAS 
    Article 

    Google Scholar
     

  • Lee, H. H. & Ham, W. S. Perioperative immunotherapy in muscle-invasive bladder most cancers. Transl. Most cancers Res. 9, 6546–6553 (2020).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yang, Q. et al. Metabolomics biotechnology, purposes, and future traits: a scientific evaluate. RSC Adv. 9, 37245–37257 (2019).

    ADS 
    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Raja, G., Jung, Y., Jung, S. H. & Kim, T. J. 1H-NMR-based metabolomics for most cancers concentrating on and metabolic engineering—a evaluate. Course of Biochem. 99, 112–122 (2020).

    CAS 
    Article 

    Google Scholar
     

  • Liu, X. et al. LC-MS-based plasma metabolomics and lipidomics analyses for differential analysis of bladder most cancers and renal cell carcinoma. Entrance. Oncol. 10, 717 (2020).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pan, Z. & Raftery, D. Evaluating and mixing NMR spectroscopy and mass spectrometry in metabolomics. Anal. Bioanal. Chem. 387, 525–527 (2007).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Ng, Ok., Stenzl, A., Sharma, A. & Vasdev, N. Urinary biomarkers in bladder most cancers: A evaluate of the present panorama and future instructions. Urol. Oncol. Semin. Orig. Investig. 39, 41–51 (2021).

    CAS 

    Google Scholar
     

  • Batista, R. et al. Biomarkers for bladder most cancers analysis and surveillance: A complete evaluate. Diagnostics 10, 39 (2020).

    CAS 
    Article 
    PubMed Central 

    Google Scholar
     

  • Walsh, M. C., Brennan, L., Malthouse, P. G., Roche, H. M. & Gibney, M. J. Impact of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of wholesome people 13. Am. J. Clin. Nutr. 84, 531–539 (2006).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Gupta, A. et al. NMR-derived focused serum metabolic biomarkers appraisal of bladder most cancers: A pre- and post-operative analysis. J. Pharm. Biomed. Anal. 183, 113134 (2020).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Bansal, N. et al. Low- and high-grade bladder most cancers willpower through human serum-based metabolomics strategy. J. Proteome Res. 12, 5839–5850 (2013).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Cao, M., Zhao, L., Chen, H., Xue, W. & Lin, D. NMR-based metabolomic evaluation of human bladder most cancers. Anal. Sci. 28, 451–456 (2012).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Amara, C. S. et al. Serum metabolic profiling recognized a definite metabolic signature in bladder most cancers people who smoke: A key metabolic enzyme related to affected person survival. Most cancers Epidemiol. Biomarkers Prev. 28, 770–781 (2019).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Vantaku, V. et al. Massive-scale profiling of serum metabolites in African American and European American sufferers with bladder most cancers reveals metabolic pathways related to affected person survival. Most cancers 125, 921–932 (2019).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Sahu, D., Lotan, Y., Wittmann, B., Neri, B. & Hansel, D. E. Metabolomics evaluation reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder most cancers. Most cancers Med. 6, 2106–2120 (2017).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tan, G. et al. Three serum metabolite signatures for diagnosing low-grade and high-grade bladder most cancers. Sci. Rep. 7, 1–11 (2017).

    ADS 
    Article 
    CAS 

    Google Scholar
     

  • Lin, L. et al. LC-MS based mostly serum metabonomic evaluation for renal cell carcinoma analysis, staging, and biomarker discovery. J. Proteome Res. 10, 1396–1405 (2011).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Zhou, Y. et al. The event of plasma pseudotargeted GC-MS metabolic profiling and its software in bladder most cancers. Anal. Bioanal. Chem. 408, 6741–6749 (2016).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Lepara, Z. et al. Serum malondialdehyde (MDA) stage as a possible biomarker of most cancers development for sufferers with bladder most cancers. Rom. J. Intern. Med. 58, 146–152 (2020).

    PubMed 

    Google Scholar
     

  • Lin, L. et al. LC-MS-based serum metabolic profiling for genitourinary most cancers classification and most cancers type-specific biomarker discovery. Proteomics 12, 2238–2246 (2012).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • MassBank of North America. Obtainable at: https://mona.fiehnlab.ucdavis.edu/. Accessed: eighth June 2022

  • Mass Spectrometry Knowledge Middle, NIST. ass Spectral Library Obtainable at: https://chemdata.nist.gov/. Accessed 1st April 2022.

  • Pang, Z. et al. MetaboAnalyst 50: Narrowing the hole between uncooked spectra and practical insights. Nucleic Acids Res. 49, W388–W396 (2021).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ho, S. Y., Phua, Ok., Wong, L. & Bin Goh, W. W. Extensions of the exterior validation for checking realized mannequin interpretability and generalizability. Patterns 1, 100129 (2020).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Okuda, S. et al. KEGG Atlas mapping for world evaluation of metabolic pathways. Nucleic Acids Res. 36, W423–W426 (2008).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Han, J., Li, Q., Chen, Y. & Yang, Y. Latest metabolomics evaluation in tumor metabolism reprogramming. Entrance. Mol. Biosci. 8, 763902 (2021).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Besiroglu, H. Lipid metabolism profiling and bladder most cancers. Metabolomics Open Entry 5, 1–4 (2015).


    Google Scholar
     

  • Wolrab, D., Jirásko, R., Chocholoušková, M., Peterka, O. & Holčapek, M. Oncolipidomics: Mass spectrometric quantitation of lipids in most cancers analysis. TrAC Tendencies Anal. Chem. 120, 10 (2019).

    Article 
    CAS 

    Google Scholar
     

  • Lu, Y. et al. Comparability of hepatic and serum lipid signatures in hepatocellular carcinoma sufferers results in the invention of diagnostic and prognostic biomarkers. Oncotarget 9, 5032 (2018).

    Article 
    PubMed 

    Google Scholar
     

  • Lee, G. B., Lee, J. C. & Moon, H. Plasma lipid profile comparability of 5 totally different cancers by nanoflow ultrahigh efficiency liquid chromatography-tandem mass spectrometry. Anal Chim Acta https://doi.org/10.1016/j.aca.2019.02.021 (2019).

    Article 
    PubMed 

    Google Scholar
     

  • Wang, X. et al. A novel human phosphatidylethanolamine-binding protein resists tumor necrosis issue α-induced apoptosis by inhibiting mitogen-activated protein kinase pathway activation and phosphatidylethanolamine externalization*. J. Biol. Chem. 279, 45855–45864 (2004).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Wang, X. et al. Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast most cancers cells to tumor necrosis factor-alpha-induced apoptosis and cell progress arrest. Clin. Most cancers Res. 11, 7545–7553 (2005).

    ADS 
    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Yao, Y. et al. Exogenous phosphatidylethanolamine induces apoptosis of human hepatoma HepG2 cells through the bcl-2/bax pathway. World J. Gastroenterol. 15, 1751 (2009).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yagi, T. et al. Challenges and inconsistencies in utilizing lysophosphatidic acid as a biomarker for ovarian most cancers. Cancers 11, 520 (2019).

    CAS 
    Article 
    PubMed Central 

    Google Scholar
     

  • Ravipati, S., Baldwin, D. R., Barr, H. L., Fogarty, A. W. & Barrett, D. A. Plasma lipid biomarker signatures in squamous carcinoma and adenocarcinoma lung most cancers sufferers. Metabolomics 11, 1600–1611 (2015).

    CAS 
    Article 

    Google Scholar
     

  • Taylor, L. A., Arends, J., Hodina, A. Ok., Unger, C. & Massing, U. Plasma lyso-phosphatidylcholine focus is decreased in most cancers sufferers with weight reduction and activated inflammatory standing. Lipids Well being Dis. 6, 1–8 (2007).

    Article 
    CAS 

    Google Scholar
     

  • Li, J. et al. Distinct plasma lipids profiles of recurrent ovarian most cancers by liquid chromatography-mass spectrometry. Oncotarget 8, 46834 (2017).

    Article 
    PubMed 

    Google Scholar
     

  • Zhang, F. et al. The predictive and prognostic values of serum amino acid ranges for clear cell renal cell carcinoma. Urol. Oncol. Semin. Orig. Investig. 35, 392–400 (2017).

    CAS 

    Google Scholar
     

  • Tan, B. et al. Metabonomics identifies serum metabolite markers of colorectal most cancers. J. Proteome Res. https://doi.org/10.1021/pr400337b (2013).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Shen, S. et al. A plasma lipidomics technique reveals perturbed lipid metabolic pathways and potential lipid biomarkers of human colorectal most cancers. J. Chromatogr. B 1068–1069, 41–48 (2017).

    Article 
    CAS 

    Google Scholar
     

  • Zhao, Z. et al. Plasma lysophosphatidylcholine ranges: potential biomarkers for colorectal most cancers. J Clin Oncol 25, 2696–2701 (2007).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Cala, M. P. et al. Multiplatform plasma fingerprinting in most cancers cachexia: a pilot observational and translational research. J. Cachexia. Sarcopenia Muscle 9, 348–357 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yao, Z. et al. Serum metabolic profiling and options of papillary thyroid carcinoma and nodular goiter. Mol. Biosyst. 7, 2608–2614 (2011).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Li, Y. et al. Thymol inhibits bladder most cancers cell proliferation through inducing cell cycle arrest and apoptosis. Biochem. Biophys. Res. Commun. 491, 530–536 (2017).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Ye, Z., Liang, Z., Mi, Q. & Guo, Y. Limonene terpenoid obstructs human bladder most cancers cell (T24 cell line) progress by inducing mobile apoptosis, caspase activation, G2/M section cell cycle arrest and stops most cancers metastasis. JBUON 25, 280–285 (2020).

    PubMed 

    Google Scholar
     

  • Wang, X., Wang, J., Rao, B. & Deng, L. I. Intestine flora profiling and fecal metabolite composition of colorectal most cancers sufferers and wholesome people. Exp. Ther. Med. 13, 2848–2854 (2017).

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Nizioł, J. et al. Metabolomic research of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA. Anal. Bioanal. Chem. 410, 3859–3869 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ganti, S. et al. Urinary acylcarnitines are altered in human kidney most cancers. Int. J. Most cancers 130, 2791–2800 (2012).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Wittmann, B. M. et al. Bladder most cancers biomarker discovery utilizing world metabolomic profiling of urine. PLoS ONE 9, e115870 (2014).

    ADS 
    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Schroeder, M. A. et al. The biking of acetyl-coenzyme A by means of acetylcarnitine buffers cardiac substrate provide: A hyperpolarized 13C magnetic resonance research. Circ. Cardiovasc. Imaging 5, 201–209 (2012).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Jin, X. et al. Prognosis of bladder most cancers and prediction of survival by urinary metabolomics. Oncotarget 5, 1635–1645 (2014).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Rodrigues, D. et al. Biomarkers in bladder most cancers: A metabolomic strategy utilizing in vitro and ex vivo mannequin programs. Int. J. Most cancers 139, 256–268 (2016).

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • RELATED ARTICLES

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    Most Popular

    Recent Comments